HOME >> BIOLOGY >> NEWS
How Super Are The "Super Aspirins"? -- New COX-2 Inhibitors May Elevate Cardiovascular Risk

A much-anticipated series of new drugs just coming to market promises to ease the pain of arthritis, menstrual cramps, headaches, and other afflictions equally as well as aspirin, ibuprofen, and related over-the-counter medications but without the sometimes serious side effects of those drugs. Stomach ulcers are among the worst of these side effects, leading to tens of thousands of hospitalizations and thousands of deaths annually.

A new study from the University of Pennsylvania Medical Center, however, raises the possibility of a downside to these so-called "super aspirins," or COX-2 inhibitors, one that could not have been detected in the clinical trials performed to date. The researchers looked closely at the pharmacology of the COX-2 inhibitors and discovered aspects of their action in the body that may elevate the risk of heart attacks, strokes, and other adverse cardiovascular events. A report on the study appears in the current issue of the Proceedings of the National Academy of Science, published January 5.

"The clinical trials designed to show that the COX-2 inhibitors work in treating arthritis have not shown evidence of a cardiovascular risk," says Garret A. FitzGerald, MD, chairman of the department of pharmacology and senior author on the study. "However, they would have been roughly an order of magnitude too small in their sample sizes to detect what we see as a possible problem associated with the use of these drugs. So, the question hangs out there for future experience: Will a cardiovascular risk emerge over time as the COX-2 inhibitors reach more and more patients?"

Aspirin and ibuprofen are members of a class of pain relievers known as nonsteroidal anti-inflammatory drugs, or NSAIDs. These drugs work by inhibiting an enzyme called cyclooxygenase, or COX. Scientists discovered early this decade that there are two forms of the enzyme, COX-1 and COX-2, and that the first, COX-1, protects the lining of t
'"/>

Contact: Franklin Hoke
hokef@mail.med.upenn.edu
215-349-5659
University of Pennsylvania School of Medicine
14-Jan-1999


Page: 1 2 3

Related biology news :

1. Super-effective jumping gene created
2. Supervised exercise program is an effective remedy for cramping leg pain
3. Superbug dynasties conquer the globe
4. Science Report: Super-crocodile crawls out of the African Cretaceous
5. Supercomputer paints electric landscape of cellular structures
6. Supercomputing center partners with Institute for Systems Biology
7. Rutgers biologist wins a $1.03 million, 5 year contract to study how microbes can help clean up Superfund sites
8. Super hearing in flies may improve hearing aid technology
9. Can Superman get off the ventilator and breathe normally?
10. Supermarket shelf labels help African Americans, others shop healthier, study finds
11. UF Scientist Seeks Super Sea Oats

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
(Date:3/22/2017)...   Neurotechnology , a provider of high-precision ... the release of the SentiVeillance 6.0 ... recognition using up to 10 surveillance, security and ... new version uses deep neural-network-based facial detection and ... a Graphing Processing Unit (GPU) for enhanced speed. ...
(Date:3/16/2017)... , March 16, 2017 CeBIT 2017 - Against identity fraud with ... Reading ... Used combined in one project, multi-biometric solutions provide a crucial ... Used combined in ... ...
Breaking Biology News(10 mins):
(Date:4/26/2017)... ... April 26, 2017 , ... ... for phase I clinical trials comes to Tampa, San Francisco and Boston in ... professionals representing FDA regulated organizations such as Pfizer Inc., Teva Pharmaceuticals, Advaxis, Inc., ...
(Date:4/26/2017)... , April 26, 2017  Genisphere LLC, ... platform, has signed a collaborative and sponsored research ... Silvia Muro . The overall goal of ... pharmacodynamics of various 3DNA designs and formulations after ... targeting diseases of the vasculature as well as ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Medicine & Rehabilitation, P.A. , proudly announced today that acclaimed physiatrist Matthew Terzella, ... duties on May 15, 2017. , Dr. Terzella completed his residency in Physical ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... recognized outstanding manufactures in 10 categories with over 30 nominees and well as ... Manufacturing presented the new award and the event was hosted by CompanyWeek and ...
Breaking Biology Technology:
Cached News: